High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-X(L) in chronic myeloid leukemia

Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a predictive biomarker of disease progression in many malignancies, including imatinib-treated chronic myeloid leukemia (CML). Although high CIP2A levels correlate with disease progression in CML, the underlying molecular mechanisms remain elu...

Descripción completa

Detalles Bibliográficos
Autores principales: Lucas, C M, Milani, M, Butterworth, M, Carmell, N, Scott, L J, Clark, R E, Cohen, G M, Varadarajan, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4895185/
https://www.ncbi.nlm.nih.gov/pubmed/26987906
http://dx.doi.org/10.1038/leu.2016.42

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4895185/
https://www.ncbi.nlm.nih.gov/pubmed/26987906
http://dx.doi.org/10.1038/leu.2016.42

Ejemplares similares